Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicaid Shift To Medicare Means Fewer Script Limits For Dual Eligibles

Executive Summary

The transfer of the "dual eligible" Medicaid population to the new Medicare prescription drug benefit will minimize the effect of arbitrary limits on the number of prescriptions available to low-income seniors, former House Energy & Commerce Committee Counsel Howard Cohen told an Alliance for Health Reform briefing Dec. 15

You may also be interested in...



Medicare Rx Overseer Will Be CMS Deputy Norwalk; Smith Is Acting CMS Head

The first stages of the implementation of the Medicare prescription drug benefit will be overseen by Centers for Medicare & Medicaid Services acting Deputy Director Leslie Norwalk

Medicare Rx Overseer Will Be CMS Deputy Norwalk; Smith Is Acting CMS Head

The first stages of the implementation of the Medicare prescription drug benefit will be overseen by Centers for Medicare & Medicaid Services acting Deputy Director Leslie Norwalk

Medicaid Directors May Seek Clarification On Rebates In Medicare Rx

The National Association of State Medicaid Directors is hoping for clarification that Medicaid rebates will be factored into "clawback" payments made by states for coverage of dual eligibles under the new Medicare drug benefit

Latest Headlines
See All
UsernamePublicRestriction

Register

PS043032

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel